Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1998 Dec;53(12):1030–1034. doi: 10.1136/thx.53.12.1030

Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids

R Stirling 1, S Kharitonov 1, D Campbell 1, D Robinson 1, S Durham 1, K Chung 1, P Barnes 1
PMCID: PMC1745124  PMID: 10195074

Abstract

BACKGROUND—Patients with difficult asthma suffer chronic moderate to severe persistent asthma symptoms despite high doses of inhaled and oral corticosteroid therapy. These patients suffer a high level of treatment and disease related morbidity but little is known about the degree of airway inflammation in these patients.
METHODS—Fifty two patients were examined to assess levels of exhaled nitric oxide (NO) as a surrogate marker of inflammatory activity in this condition. From this group, 26 patients were defined with severe symptoms and current physiological evidence of reversible airway obstruction requiring high dose inhaled (⩾2000 µg beclomethasone dipropionate (BDP) equivalent) or oral steroid therapy to maintain disease control.
RESULTS—Exhaled NO levels were higher in subjects with difficult asthma (mean 13.9 ppb, 95% CI 9.3 to 18.5) than in normal controls (7.4 ppb, 95% CI 6.9 to 7.8; p<0.002), but lower than levels in steroid naive mild asthmatics (36.9 ppb, 95% CI 34.6 to 39.3; p<0.001). Prednisolone treated patients had higher exhaled NO levels than patients only requiring inhaled corticosteroids (17.5ppb, 95% CI 11.1 to 24.0 versus 7.2 ppb, 95% CI 4.6 to 9.8; p= 0.016), suggesting greater disease severity in this group. Non-compliance with prednisolone treatment was observed in 20% of patients but this did not explain the difference between the treatment groups. Exhaled NO levels were closely correlated with symptom frequency (p = 0.03) and with rescue β agonist use (p<0.002), but they did not correlate with lung function.
CONCLUSIONS—Exhaled NO may serve as a useful complement to lung function and symptomatology in the assessment of patients with chronic severe asthma, and in the control and rationalisation of steroid therapy in these patients.



Full Text

The Full Text of this article is available as a PDF (152.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlstedt S. Clinical application of eosinophilic cationic protein in asthma. Allergy Proc. 1995 Mar-Apr;16(2):59–62. doi: 10.2500/108854195778771426. [DOI] [PubMed] [Google Scholar]
  2. Antczak A., Nowak D., Shariati B., Król M., Piasecka G., Kurmanowska Z. Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients. Eur Respir J. 1997 Jun;10(6):1235–1241. doi: 10.1183/09031936.97.10061235. [DOI] [PubMed] [Google Scholar]
  3. Barnes P. J., Kharitonov S. A. Exhaled nitric oxide: a new lung function test. Thorax. 1996 Mar;51(3):233–237. doi: 10.1136/thx.51.3.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown P. J., Greville H. W., Finucane K. E. Asthma and irreversible airflow obstruction. Thorax. 1984 Feb;39(2):131–136. doi: 10.1136/thx.39.2.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chapman I. D., Foster A., Morley J. The relationship between inflammation and hyperreactivity of the airways in asthma. Clin Exp Allergy. 1993 Mar;23(3):168–171. doi: 10.1111/j.1365-2222.1993.tb00877.x. [DOI] [PubMed] [Google Scholar]
  6. Chung K. F. Management of difficult asthma. Br J Hosp Med. 1994 Feb 2;51(3):80–81. [PubMed] [Google Scholar]
  7. Dahl R., Martinati L. C., Boner A. L. Monitoring of bronchial asthma. Respir Med. 1997 Nov;91(10):581–586. doi: 10.1016/s0954-6111(97)90003-2. [DOI] [PubMed] [Google Scholar]
  8. Djukanović R., Homeyard S., Gratziou C., Madden J., Walls A., Montefort S., Peroni D., Polosa R., Holgate S., Howarth P. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am J Respir Crit Care Med. 1997 Mar;155(3):826–832. doi: 10.1164/ajrccm.155.3.9117012. [DOI] [PubMed] [Google Scholar]
  9. Djukanović R., Wilson J. W., Britten K. M., Wilson S. J., Walls A. F., Roche W. R., Howarth P. H., Holgate S. T. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992 Mar;145(3):669–674. doi: 10.1164/ajrccm/145.3.669. [DOI] [PubMed] [Google Scholar]
  10. Dohlman A. W., Black H. R., Royall J. A. Expired breath hydrogen peroxide is a marker of acute airway inflammation in pediatric patients with asthma. Am Rev Respir Dis. 1993 Oct;148(4 Pt 1):955–960. doi: 10.1164/ajrccm/148.4_Pt_1.955. [DOI] [PubMed] [Google Scholar]
  11. Drazen J. M., O'Brien J., Sparrow D., Weiss S. T., Martins M. A., Israel E., Fanta C. H. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis. 1992 Jul;146(1):104–108. doi: 10.1164/ajrccm/146.1.104. [DOI] [PubMed] [Google Scholar]
  12. Hamid Q., Springall D. R., Riveros-Moreno V., Chanez P., Howarth P., Redington A., Bousquet J., Godard P., Holgate S., Polak J. M. Induction of nitric oxide synthase in asthma. Lancet. 1993 Dec 18;342(8886-8887):1510–1513. doi: 10.1016/s0140-6736(05)80083-2. [DOI] [PubMed] [Google Scholar]
  13. Jeffery P. K., Wardlaw A. J., Nelson F. C., Collins J. V., Kay A. B. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis. 1989 Dec;140(6):1745–1753. doi: 10.1164/ajrccm/140.6.1745. [DOI] [PubMed] [Google Scholar]
  14. Kharitonov S. A., Chung K. F., Evans D., O'Connor B. J., Barnes P. J. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1773–1780. doi: 10.1164/ajrccm.153.6.8665033. [DOI] [PubMed] [Google Scholar]
  15. Kharitonov S. A., Yates D. H., Barnes P. J. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996 Jan;153(1):454–457. doi: 10.1164/ajrccm.153.1.8542158. [DOI] [PubMed] [Google Scholar]
  16. Kharitonov S. A., Yates D., Robbins R. A., Logan-Sinclair R., Shinebourne E. A., Barnes P. J. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994 Jan 15;343(8890):133–135. doi: 10.1016/s0140-6736(94)90931-8. [DOI] [PubMed] [Google Scholar]
  17. Kharitonov S., Alving K., Barnes P. J. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J. 1997 Jul;10(7):1683–1693. doi: 10.1183/09031936.97.10071683. [DOI] [PubMed] [Google Scholar]
  18. Laitinen L. A., Laitinen A., Heino M., Haahtela T. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. Am Rev Respir Dis. 1991 Feb;143(2):423–427. doi: 10.1164/ajrccm/143.2.423. [DOI] [PubMed] [Google Scholar]
  19. Lundgren R., Söderberg M., Hörstedt P., Stenling R. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J. 1988 Dec;1(10):883–889. [PubMed] [Google Scholar]
  20. Massaro A. F., Gaston B., Kita D., Fanta C., Stamler J. S., Drazen J. M. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med. 1995 Aug;152(2):800–803. doi: 10.1164/ajrccm.152.2.7633745. [DOI] [PubMed] [Google Scholar]
  21. Peat J. K., Woolcock A. J., Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis. 1987 Mar;70(3):171–179. [PubMed] [Google Scholar]
  22. Pizzichini M. M., Pizzichini E., Clelland L., Efthimiadis A., Mahony J., Dolovich J., Hargreave F. E. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med. 1997 May;155(5):1501–1508. doi: 10.1164/ajrccm.155.5.9154849. [DOI] [PubMed] [Google Scholar]
  23. Redington A. E., Howarth P. H. Airway wall remodelling in asthma. Thorax. 1997 Apr;52(4):310–312. doi: 10.1136/thx.52.4.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Robinson D. S., Bentley A. M., Hartnell A., Kay A. B., Durham S. R. Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax. 1993 Jan;48(1):26–32. doi: 10.1136/thx.48.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Roche W. R., Beasley R., Williams J. H., Holgate S. T. Subepithelial fibrosis in the bronchi of asthmatics. Lancet. 1989 Mar 11;1(8637):520–524. doi: 10.1016/s0140-6736(89)90067-6. [DOI] [PubMed] [Google Scholar]
  26. Ronchi M. C., Piragino C., Rosi E., Stendardi L., Tanini A., Galli G., Duranti R., Scano G. Do sputum eosinophils and ECP relate to the severity of asthma? Eur Respir J. 1997 Aug;10(8):1809–1813. doi: 10.1183/09031936.97.10081809. [DOI] [PubMed] [Google Scholar]
  27. Roquet A., Halldén G., Ihre E., Hed J., Zetterström O. Eosinophil activity markers in peripheral blood have high predictive value for bronchial hyperreactivity in patients with suspected mild asthma. Allergy. 1996 Jul;51(7):482–488. doi: 10.1111/j.1398-9995.1996.tb04654.x. [DOI] [PubMed] [Google Scholar]
  28. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997 Jan-Feb;17(1):22–37. [PubMed] [Google Scholar]
  29. Siergiejko Z., Zietkowski Z., Chyrek-Borowska S. Wpływ flunizolidu na nasilenie objawów klinicznych, parametry spirometryczne, konsumpcje lek-ow beta 2-adrenergicznych oraz steenie kortyzolu i ECP w surowicy chorych na astme oskrzelowa. Pneumonol Alergol Pol. 1995;63 (Suppl 2):76–82. [PubMed] [Google Scholar]
  30. Sont J. K., Han J., van Krieken J. M., Evertse C. E., Hooijer R., Willems L. N., Sterk P. J. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax. 1996 May;51(5):496–502. doi: 10.1136/thx.51.5.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wilson J. W., Li X., Pain M. C. The lack of distensibility of asthmatic airways. Am Rev Respir Dis. 1993 Sep;148(3):806–809. doi: 10.1164/ajrccm/148.3.806. [DOI] [PubMed] [Google Scholar]
  32. Woolcock A. J. How does inflammation cause symptoms? Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 2):S21–S22. doi: 10.1164/ajrccm/153.6_Pt_2.S21. [DOI] [PubMed] [Google Scholar]
  33. Yates D. H., Kharitonov S. A., Barnes P. J. Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Eur Respir J. 1997 Jul;10(7):1483–1488. doi: 10.1183/09031936.97.10071483. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES